AU5702201A - Abeta<sub>42</sub> lowering agents - Google Patents

Abeta<sub>42</sub> lowering agents

Info

Publication number
AU5702201A
AU5702201A AU5702201A AU5702201A AU5702201A AU 5702201 A AU5702201 A AU 5702201A AU 5702201 A AU5702201 A AU 5702201A AU 5702201 A AU5702201 A AU 5702201A AU 5702201 A AU5702201 A AU 5702201A
Authority
AU
Australia
Prior art keywords
sub
abeta
lowering agents
lowering
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU5702201A
Other languages
English (en)
Inventor
Edward Hao Mang Koo
Todd Eliot Golde
Douglas Roger Galasko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Publication of AU5702201A publication Critical patent/AU5702201A/xx
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
AU5702201A 2000-04-13 2001-04-12 Abeta<sub>42</sub> lowering agents Pending AU5702201A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19661700P 2000-04-13 2000-04-13
PCT/US2001/011956 WO2001078721A1 (en) 2000-04-13 2001-04-12 Aβ42 LOWERING AGENTS

Publications (1)

Publication Number Publication Date
AU5702201A true AU5702201A (en) 2001-10-30

Family

ID=22726126

Family Applications (2)

Application Number Title Priority Date Filing Date
AU5702201A Pending AU5702201A (en) 2000-04-13 2001-04-12 Abeta<sub>42</sub> lowering agents
AU2001257022A Ceased AU2001257022B2 (en) 2000-04-13 2001-04-12 Abeta 42 lowering agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001257022A Ceased AU2001257022B2 (en) 2000-04-13 2001-04-12 Abeta 42 lowering agents

Country Status (6)

Country Link
US (5) US6911466B2 (enExample)
EP (1) EP1284729A4 (enExample)
JP (1) JP2003530437A (enExample)
AU (2) AU5702201A (enExample)
CA (1) CA2406383A1 (enExample)
WO (1) WO2001078721A1 (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20060004086A1 (en) * 2000-04-13 2006-01-05 Mayo Foundation For Medical Education And Research Method of reducing Abeta42 and treating diseases
WO2002048150A2 (en) 2000-11-02 2002-06-20 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
WO2002038142A2 (en) * 2000-11-08 2002-05-16 Massachusetts Institute Of Technology Serotonergic compositions and methods for treatment of mild cognitive impairment
EP1469810A4 (en) * 2002-01-04 2009-01-14 Univ Rockefeller COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING BETA-AMYLOID PEPTIDE-RELATED DISORDERS
US20040127471A1 (en) * 2002-09-17 2004-07-01 Barry Reisberg Methods of treating age associated memory impairment (AAMI), mild cognitive impairment (MCI), and dementias with cell cycle inhibitors
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
EP1553932A2 (en) * 2002-10-21 2005-07-20 Ramot at Tel Aviv University Ltd. Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators
JP2006517925A (ja) * 2003-01-14 2006-08-03 メルク　エンド　カムパニー　インコーポレーテッド Ａβ４２低下薬としてのジェミナル二置換ＮＳＡＩＤ誘導体
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
KR101088272B1 (ko) 2003-02-21 2011-11-30 키에시 파르마슈티시 엣스. 피. 에이. 신경 퇴행성 질환의 치료를 위한 1-페닐알캔카복실산추출물
ITMI20030312A1 (it) * 2003-02-21 2004-08-22 Chiesi Farma Spa Derivati di acidi 2-fenil-2-alchil-acetici per il trattamento della malattia di alzheimer.
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2004087051A2 (en) * 2003-03-27 2004-10-14 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
AT413944B (de) * 2003-05-27 2006-07-15 Binder Eva Dkfm Verwendung von oxicam-verbindungen
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
US20050171207A1 (en) * 2003-09-26 2005-08-04 Myriad Genetics, Incorporated Method and composition for combination treatment of neurodegenerative disorders
JP4851348B2 (ja) * 2004-02-23 2012-01-11 イーライ リリー アンド カンパニー 抗Ａβ抗体
WO2005092062A2 (en) * 2004-03-19 2005-10-06 Myriad Genetics, Inc. Compounds for neurodegenerative disorders
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2005108683A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
GB0410238D0 (en) * 2004-05-07 2004-06-09 Merck Sharp & Dohme Therapeutic agents
WO2005110963A1 (en) * 2004-05-19 2005-11-24 Cellzome Ag (biphenyl-3-yl)-carboxylic acids and derivatives thereof and their use in therapy
EP1750719A2 (en) 2004-05-19 2007-02-14 Boehringer Ingelheim International GmbH Treatment of diseases associated with altered level of amyloid beta peptides
EP1604970A1 (en) * 2004-05-19 2005-12-14 Cellzome Ag 2-(Biphenyl-3-yl)-carboxylic acids of gamma-secretase-modulating activity
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
EP1650183A1 (en) * 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
EP1657232A1 (en) * 2004-11-05 2006-05-17 Cellzome Ag Use of S-enantiomers of alpha-sustituted aryl acetic acids for the prevention of Alzheimer's disease
US20060241038A1 (en) * 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
EP1876900A4 (en) * 2005-05-02 2009-06-24 Univ Columbia PHOSPHOINOSITIDE MODULATION FOR THE TREATMENT OF ALZHEIMER DISEASE
JP2008545663A (ja) * 2005-05-27 2008-12-18 クイーンズ ユニバーシティ アット キングストン タンパク質フォールディング障害の治療
EP1746092A1 (en) 2005-07-22 2007-01-24 Exonhit Therapeutics SA Compounds and methods for treatment of amyloid-B-peptide related disorders
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
WO2007056580A2 (en) * 2005-11-08 2007-05-18 Pharmadyn, Inc. Methods and compositions for treating diseases associated with pathogenic proteins
EP1847524B1 (en) 2006-04-21 2009-10-14 Cellzome Limited Terphenyl derivatives for treatment of Alzheimer's disease
PT1849762E (pt) 2006-04-21 2009-09-16 Cellzome Ltd Ácidos bifenilcarboxílicos substituídos e seus derivados
JP5135588B2 (ja) * 2006-06-02 2013-02-06 国立大学法人大阪大学 延長型アミロイドβ産生抑制剤
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
JP5317405B2 (ja) * 2006-10-03 2013-10-16 知之 西崎 脳機能の改善剤及びそのスクリーニング方法
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
DK2132188T3 (da) 2007-03-07 2012-02-27 Janssen Pharmaceutica Nv Substituerede phenoxy-N-alkylerede thiazolidindioner som østrogenrelaterede receptor-alfa-modulatorer
CL2008000667A1 (es) 2007-03-07 2008-11-03 Janssen Pharmaceutica Nv Compuestos derivados de fenoxi aminotiazolonas sustituidas, modulares de receptores alfa relacionados con estrogenos; composion farmaceutica que comprende a dichos compuestos; y sus uso para tratar cancer, sindrome metabolico, obesidad, diabetes.
EP2134323A4 (en) * 2007-04-06 2012-03-07 Rhode Island Education REDUCTION OF PROTEINS ASSOCIATED WITH ALZHEIMER DISEASE BY INTERRUPTING GENE TRANSCRIPTIONS WITH A SMALL MOLECULE
WO2009037707A2 (en) 2007-09-20 2009-03-26 Ramot At Tel Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
DK2215044T3 (da) 2007-10-17 2012-11-26 Cellzome Ltd Biphenylcarboxylsyrer og derivater deraf
EP2212277B1 (en) * 2007-10-19 2016-08-31 Janssen Pharmaceutica, N.V. Amine linked modulators of y-secretase
JP5543353B2 (ja) 2007-10-19 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ γ−セクレターゼのアミド結合調節物質
EA201070497A1 (ru) * 2007-10-19 2010-12-30 Янссен Фармацевтика, Н.В. Промежуточные продукты мгс
US8692017B2 (en) * 2007-10-19 2014-04-08 Janssen Pharmaceutica, N.V. Carbon linked modulators of gamma-secretase
ATE543799T1 (de) 2007-10-19 2012-02-15 Janssen Pharmaceutica Nv Piperidinyl- und piperazinylmodulatoren von g- sekretase
US7968725B2 (en) 2008-07-22 2011-06-28 Janssen Pharmaceutica N.V. Pyridinyl modulators of γ-secretase
CN102271669A (zh) * 2008-11-13 2011-12-07 基因改造有限责任公司 非大脑组织中β-淀粉样肽负载的改性
WO2010071741A1 (en) 2008-12-16 2010-06-24 Merck Sharp & Dohme Corp. Triazole derivatives for treatment of alzheimer's disease
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN102325765B (zh) 2009-02-06 2014-12-24 杨森制药公司 作为γ-分泌酶调节剂的取代的双环杂环化合物
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
EA019702B1 (ru) 2009-05-07 2014-05-30 Янссен Фармасьютикалз, Инк. Замещенные производные индазола и азаиндазола в качестве модуляторов гамма-секретазы
WO2011006903A1 (en) 2009-07-15 2011-01-20 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
PH12012501381A1 (en) 2010-01-15 2012-10-22 Janssen Pharmaceuticals Inc Novel substituted bicyclic triazole derivatives as gamma secretase modulators
KR101924162B1 (ko) * 2010-03-15 2018-11-30 버지니아 커먼웰스 유니버시티 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손
ES2536442T3 (es) 2011-03-24 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados novedosos de triazolil piperazina y triazolil piperidina como moduladores de la gamma secretasa
WO2012135650A1 (en) * 2011-04-01 2012-10-04 Southern Research Institute Derivatives of sulindac, use thereof and preparation thereof
CN103874702B (zh) 2011-07-15 2015-12-09 杨森制药公司 作为γ分泌酶调节剂的经取代的吲哚衍生物
EP2586436A1 (en) * 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
MX352749B (es) 2011-11-01 2017-12-06 Modgene Llc Composiciones y metodos para la reduccion de la carga amiloide-beta.
CN104583208B (zh) 2012-05-16 2016-09-28 杨森制药公司 可用于治疗(尤其是)阿尔茨海默病的取代的3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物
EP2687528A1 (en) 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US9649360B2 (en) * 2012-12-19 2017-05-16 Shiga University Of Medical Science Pharmaceutical composition for the treatment and/or prevention of disease involving abnormal accumulation of amyloid β protein
WO2014096212A1 (en) 2012-12-20 2014-06-26 Janssen Pharmaceutica Nv NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-α]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS
KR102171710B1 (ko) 2013-01-17 2020-10-30 얀센 파마슈티카 엔.브이. 감마 세크레타제 조절 인자로서의 신규 치환 피리도-피페라지논 유도체
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
US11465978B2 (en) 2013-09-11 2022-10-11 The Administrators Of The Tulane Educational Fund Anthranilic amides and the use thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
CN103976989A (zh) * 2014-05-29 2014-08-13 崔德华 氨苯砜在制备α-分泌酶增强中的应用
US10441573B2 (en) 2015-12-09 2019-10-15 Brandeis University DBH inhibitors for treating memory loss
CA3032255A1 (en) * 2016-07-28 2018-02-01 Aurin Biotech Inc. Salivary abeta42 levels as prognostic indicators for alzheimer's disease
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
CN111565711B (zh) 2017-07-20 2023-01-03 阿茨治疗股份有限公司 色甘酸钠和布洛芬的粉末化制剂
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
US12612391B2 (en) 2020-12-28 2026-04-28 The General Hospital Corporation Cromolyn derivatives and uses thereof
KR102784009B1 (ko) * 2021-01-28 2025-03-20 닥터노아바이오텍 주식회사 콜린에스터라제 억제제 및 항산화제를 포함하는 뇌질환 치료용 약학적 복합 조성물
CN118221668B (zh) * 2024-03-19 2026-06-02 华南农业大学 一种含2-氨基-1,3,4-噻二唑的吲哚美辛衍生物及其制备方法和应用

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1091403A (en) * 1964-01-24 1967-11-15 Boots Pure Drug Co Ltd Therapeutically active phenylalkane derivatives
FR1546478A (fr) * 1967-01-27 1968-11-22 Rhone Poulenc Sa Nouveaux dérivés de l'acide benzoyl-3 phénylacétique et leur préparation
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
NL7503310A (nl) * 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4089969A (en) * 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4209638A (en) * 1977-03-08 1980-06-24 The Boots Company Limited Preparation of therapeutic agents
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4337273A (en) * 1980-05-15 1982-06-29 Thomas Jefferson University Methods of increasing coronary blood flow through vasodilation by flurbiprofen
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4686237A (en) * 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
US4668794A (en) * 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
DE3682136D1 (de) * 1985-07-31 1991-11-28 Hoechst Ag N-substituierte 5-nitroanthranilsaeuren, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen.
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
EP0284612B1 (en) * 1986-01-30 1991-07-24 University of Utah Treatment of bone loss
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
DE3824353A1 (de) * 1988-07-19 1990-01-25 Paz Arzneimittelentwicklung Verfahren zur trennung von gemischen enantiomerer arylpropionsaeuren
JPH0248526A (ja) * 1988-08-08 1990-02-19 Sumitomo Pharmaceut Co Ltd インドメタシン注射剤およびその製造方法
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5213738A (en) * 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
JPH06507782A (ja) * 1990-06-15 1994-09-08 サイオス　ノバ　インコーポレイテッド アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
US5015764A (en) * 1990-06-18 1991-05-14 Ethyl Corporation Preparation of optically active aliphatic carboxylic acids
DE4028906A1 (de) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US6746678B1 (en) * 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
DE69206306T2 (de) * 1991-04-08 1996-06-13 Sumitomo Chemical Co Optisch aktive Sekundär-Aminverbindung, Verfahren zur Herstellung einer optisch aktiven Sekundär-Aminverbindung und Verfahren zur Herstellung optisch aktiver Carbonsäure durch die Verwendung dieser Verbindung.
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
US5235100A (en) * 1992-01-24 1993-08-10 Ethyl Corporation Preparation of optically active aliphatic carboxylic acids
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5455169A (en) * 1992-06-04 1995-10-03 Alzheimer's Institute Of America, Inc. Nucleic acids for diagnosing and modeling Alzheimer's disease
NZ253631A (en) * 1992-06-30 1997-02-24 Procter & Gamble Pharma Phosphonate or nsaid pharmaceutical compositions for treating arthritis
IT1256450B (it) * 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
EP0672030B1 (en) * 1992-12-02 1997-04-16 Knoll AG Process for preparing substantially pure enantiomers of phenylpropionic acids
US5380867A (en) * 1992-12-02 1995-01-10 Hoechst Celanese Corporation Selective precipitation of α-aryl carboxylic acid salts
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
GB9314693D0 (en) * 1993-07-15 1993-08-25 Smithkline Beecham Plc Naphthyl derivatives for treatment method
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
GB9315856D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5574022A (en) * 1994-04-14 1996-11-12 The Center For Innovative Technology Method of attenuating physical damage to the spinal cord
US6025395A (en) * 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US5643960A (en) * 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5935860A (en) * 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
US5626838A (en) * 1995-03-13 1997-05-06 The Procter & Gamble Company Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5750564A (en) * 1995-09-12 1998-05-12 Hellberg; Mark Anti-oxidant esters of non-steroidal anti-inflammatory agents
US5897880A (en) * 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
GB9523833D0 (en) * 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
IT1277741B1 (it) * 1995-12-28 1997-11-12 Dompe Spa Composizioni farmaceutiche parenterali contenenti sali di alchilammonio di acidi 2-arilpropionici
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US6255347B1 (en) * 1996-06-21 2001-07-03 Advanced Research And Technology Institute Methods and compositions comprising R-ibuprofen
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
CA2279651A1 (en) * 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
HRP970485A2 (en) * 1996-09-13 1998-08-31 Joerg Rosenberg Process for producing solid pharmaceutical forms
US5898094A (en) * 1996-10-21 1999-04-27 University Of South Florida Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
US5858738A (en) * 1996-11-07 1999-01-12 Merck & Co., Inc. Ermophilane sesquiterpenoids as HIV intergrase inhibitors
WO1998027972A2 (en) * 1996-12-23 1998-07-02 Texas A & M University Anti-amyloidogenic agents
CA2283255C (en) * 1997-03-10 2007-01-02 Loma Linda University Medical Center Use of r-nsaid's for the prevention of alzheimer's disease
GB9710521D0 (en) * 1997-05-22 1997-07-16 Boots Co Plc Process
WO1999029668A1 (en) * 1997-12-05 1999-06-17 Eisai Co., Ltd. Donepezil polycrystals and process for producing the same
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
CA2319131A1 (en) * 1998-01-26 1999-07-29 Walter H. Moos Mitochondria protecting agents for treating mitochondria associated diseases
IT1298214B1 (it) * 1998-01-28 1999-12-20 Dompe Spa Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche.
US6051587A (en) * 1998-04-16 2000-04-18 Medicure, Inc. Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
US6054451A (en) * 1998-04-21 2000-04-25 Algos Pharmaceutical Corporation Analgesic composition and method for alleviating pain
US6160618A (en) * 1998-06-19 2000-12-12 Board Of Regents, The University Of Texas System Hyperspectral slide reader
ES2281981T3 (es) * 1998-09-03 2007-10-01 Loma Linda University Medical Center Composicion farmaceutica y uso de aines para tratar la inflamacion.
EP1126838A4 (en) * 1998-10-30 2005-02-16 Nitromed Inc NITROSIS AND NITROSYAL NON-STEROID ANTI-INFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
IN189741B (enExample) * 1998-11-09 2003-04-19 Council Scient Ind Res
ES2194536T3 (es) * 1998-11-13 2003-11-16 Lilly Co Eli Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos.
US6726929B1 (en) * 1998-12-18 2004-04-27 Basf Aktiengesellschaft Pharmaceutical mixture comprising a profen
US6383527B1 (en) * 1999-03-04 2002-05-07 Nps Pharmaceuticals, Inc. Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID
DK1163234T3 (da) * 1999-03-24 2006-02-27 Scherer Technologies Inc R P Farmaceutiske formuleringer med forbedret vandoplöselighed
US6372760B1 (en) * 1999-03-31 2002-04-16 Eisai Co., Ltd. Stabilized composition comprising antidementia medicament
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6368618B1 (en) * 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20060004086A1 (en) * 2000-04-13 2006-01-05 Mayo Foundation For Medical Education And Research Method of reducing Abeta42 and treating diseases
US6355666B1 (en) * 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
NZ524252A (en) * 2000-07-20 2004-03-26 Lauras As Cox-2 inhibitors for treating HIV and AIDS
DE10047319A1 (de) * 2000-09-25 2002-04-18 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen, welche durch die Hemmung der Aktivierung des nukleären Transkriptionsfaktors AP-1 therapeutisch beeinflußt werden können
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
US20040049134A1 (en) * 2002-07-02 2004-03-11 Tosaya Carol A. System and methods for treatment of alzheimer's and other deposition-related disorders of the brain
US7074826B2 (en) * 2002-10-07 2006-07-11 Encore Pharmaceuticals, Inc. R-NSAID esters and their use
KR101088272B1 (ko) * 2003-02-21 2011-11-30 키에시 파르마슈티시 엣스. 피. 에이. 신경 퇴행성 질환의 치료를 위한 1-페닐알캔카복실산추출물
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
US20070078114A1 (en) * 2005-09-02 2007-04-05 Myriad Genetics, Incorporated Combination therapy for alzheimer's disease and other diseases

Also Published As

Publication number Publication date
AU2001257022B2 (en) 2005-02-03
US7097998B2 (en) 2006-08-29
US20070253905A1 (en) 2007-11-01
JP2003530437A (ja) 2003-10-14
EP1284729A4 (en) 2007-12-19
CA2406383A1 (en) 2001-10-25
WO2001078721A1 (en) 2001-10-25
US20050089945A1 (en) 2005-04-28
US6911466B2 (en) 2005-06-28
US20020128319A1 (en) 2002-09-12
US20050186559A1 (en) 2005-08-25
EP1284729A1 (en) 2003-02-26
US20070253906A1 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
IL154705A0 (en) Polyarylcarboxamides useful as lipid lowering agents
TW595857U (en) 091219345
AU6692701A (en) 3&#39;-prodrugs of 2&#39;-deoxy-beta-L-nucleosides
GB0229946D0 (en) Centraliser
IL156098A0 (en) Serotonergic agents
GB2360535B (en) Centraliser
GC0000312A (en) Biphenylcarboxamides useful as lipid lowering agents
AU2001280135A1 (en) Fibrinogen lowering agents
GB0021821D0 (en) Drive&#39;s-yer-nuts
HUP0401290A3 (en) Low-lipoxygenase 1 barley
AU145171S (en) Sill
GB0021040D0 (en) Drills
GB0112298D0 (en) &#34;Hinge assembly&#34;
GB0022434D0 (en) Microscope
AU2521P (en) H 2/206 Hardenbergia violacea
GB0129650D0 (en) &#39;DVT-nomore&#39;
GB0019112D0 (en) Biopower 2
GB0015249D0 (en) Telecommunications 1
GB0003963D0 (en) Muscarinic agents
AU1681P (en) Lois Cuphea hyssopifolia
GB0111630D0 (en) Unistore 800
GB0131085D0 (en) Kerb grab &#34;manual operation&#34;
GB0125582D0 (en) Fotwear designs 4
GB0003927D0 (en) J H L wheel-safe
GB0017599D0 (en) D 7&#39;s 2000